Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
McKinsey
Boehringer Ingelheim
Harvard Business School
Baxter

Last Updated: August 10, 2022

Details for Patent: 7,655,637


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 7,655,637
Title:N-pyrazole A.sub.2A receptor agonists
Abstract:2-adenosine N-pyrazole compounds having the following formula: ##STR00001## wherein R.sup.1.dbd.CH.sub.2OH; R.sup.2 is hydrogen; R.sup.3 is selected from the group consisting of CO.sub.2R.sup.20; --CONR.sup.7R.sup.8 ,and aryl wherein the aryl substituent is optionally substituted with one substituent selected from the group consisting of halo, C .sub.1-3alkyl and OR.sup.20;R.sup.4 is hydrogen; R.sup.7 is selected from hydrogen, and C.sub.1-3alkyl; R.sup.8 is hydrogen; and R.sup.20 is selected from hydrogen and methyl as well as methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart are disclosed.
Inventor(s): Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Fremont, CA), Palle; Venkata (Pune, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Palo Alto, Inc. (Foster City, CA)
Application Number:11/588,834
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 7,655,637

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,655,637

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 024441 See Plans and Pricing
Austria 256141 See Plans and Pricing
Australia 7132400 See Plans and Pricing
Australia 760806 See Plans and Pricing
Belgium 2011C004 See Plans and Pricing
Brazil 0011856 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts
AstraZeneca
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.